Table 1.
Means (Standard Deviations [SDs]) for Each Physical Health Outcome by at Least 1‐ and 2‐Level Reductions at Each Assessment Time Point
| Outcome | No change or increase mean (SD) | At least 1‐level reduction mean (SD) | 1‐level reduction, no change, or increase mean (SD) | At least 2‐level reduction mean (SD) |
|---|---|---|---|---|
| SBP (mm/Hg) | ||||
| Week 16 | 137.9 (17.6) | 129.8 (16.6) | 134.2 (17.1) | 129.5 (16.6) |
| Week 26 | 138.6 (17.5) | 130.3 (17.9) | 135.5 (19.2) | 129.9 (17.3) |
| Week 52 | 136.7 (16.9) | 130.6 (17.2) | 134.4 (17.7) | 130.3 (16.9) |
| AST (IU/l) | ||||
| Week 16 | 41.0 (35.7) | 28.2 (16.0) | 36.2 (29.1) | 27.7 (14.7) |
| Week 26 | 38.5 (34.9) | 29.6 (26.8) | 35.4 (29.8) | 29.2 (27.7) |
| Week 52 | 40.3 (37.5) | 31.2 (29.9) | 37.7 (33.8) | 30.5 (30.3) |
| ALT (IU/l) | ||||
| Week 16 | 40.8 (32.6) | 30.8 (23.5) | 38.0 (28.9) | 30.1 (23.1) |
| Week 26 | 40.8 (38.9) | 30.9 (22.2) | 36.7 (31.5) | 30.8 (22.9) |
| Week 52 | 41.3 (29.7) | 33.9 (33.9) | 40.4 (30.8) | 32.8 (34.3) |
| GGT (IU/l) | ||||
| Week 16 | 145.1 (467.1) | 43.5 (61.9) | 87.3 (303.6) | 42.9 (63.3) |
| Week 26 | 86.6 (223.3) | 47.2 (73.2) | 73.8 (172.6) | 44.9 (72.8) |
| Week 52 | 108.6 (245.4) | 53.4 (79.4) | 29.5 (197.3) | 51.2 (75.1) |
All numbers are observed (percentages are based on valid number of cases) with no imputation for missing data. Biomarker assessments were conducted at the end of treatment (week 16 after baseline) and at 2 assessments after treatment: 10 weeks posttreatment (postbaseline week 26) and 36 weeks posttreatment (postbaseline week 52). ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, γ‐glutamyltransferase; IU/l, international units per liter; SBP, systolic blood pressure.